NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS

NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS

Insulin glargine, synthesized using recombinant DNA technology in a concentration of 100 U/ml, was the first once-daily longacting insulin analogue introduced into clinical practice in 2000. Glargin has a well-established record of efficacy and safety and is the most widely used insulin worldwide. I...

Full description

Bibliographic Details
Main Authors: I. V. Kononenko, O. M. Smirnova
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-01-01
Series:Медицинский совет
Subjects:
diabetes mellitus
insulin therapy
long-acting insulin
Online Access:https://www.med-sovet.pro/jour/article/view/2248
id doaj-472ca0256956498cae1dfb379381c112
record_format Article
spelling doaj-472ca0256956498cae1dfb379381c1122021-07-28T13:29:33ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-01-0102016016510.21518/2079-701X-2017-20-160-1652225NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINSI. V. Kononenko0O. M. Smirnova1Endocrinology Research Center of the Ministry of Health of Russia; Sechenov First Moscow State Medical University.Endocrinology Research Center of the Ministry of Health of Russia; Sechenov First Moscow State Medical University.Insulin glargine, synthesized using recombinant DNA technology in a concentration of 100 U/ml, was the first once-daily longacting insulin analogue introduced into clinical practice in 2000. Glargin has a well-established record of efficacy and safety and is the most widely used insulin worldwide. In February 2015, the drug lost its US patent protection, which opened the door for biosimilar competitors.https://www.med-sovet.pro/jour/article/view/2248diabetes mellitusinsulin therapylong-acting insulin
collection DOAJ
language Russian
format Article
sources DOAJ
author I. V. Kononenko
O. M. Smirnova
spellingShingle I. V. Kononenko
O. M. Smirnova
NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS
Медицинский совет
diabetes mellitus
insulin therapy
long-acting insulin
author_facet I. V. Kononenko
O. M. Smirnova
author_sort I. V. Kononenko
title NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS
title_short NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS
title_full NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS
title_fullStr NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS
title_full_unstemmed NEW DRUG IN THE EVOLUTION OF LONG-ACTING INSULINS
title_sort new drug in the evolution of long-acting insulins
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2018-01-01
description Insulin glargine, synthesized using recombinant DNA technology in a concentration of 100 U/ml, was the first once-daily longacting insulin analogue introduced into clinical practice in 2000. Glargin has a well-established record of efficacy and safety and is the most widely used insulin worldwide. In February 2015, the drug lost its US patent protection, which opened the door for biosimilar competitors.
topic diabetes mellitus
insulin therapy
long-acting insulin
url https://www.med-sovet.pro/jour/article/view/2248
work_keys_str_mv AT ivkononenko newdrugintheevolutionoflongactinginsulins
AT omsmirnova newdrugintheevolutionoflongactinginsulins
_version_ 1721274026432659456

Similar Items